Cediranib Prolongs Survival in Recurrent Glioblastoma Cancer Consultants, ID - May 22, 2008 The investigative agent cediranib (AZD2171) appears to prolong survival among patients with recurrent glioblastoma
Cediranib Prolongs Survival in Recurrent Glioblastoma
AZD2171 is a potent VEGF signaling pathway inhibitor. See this article that describes the collaboration that led to better insight into how AZD2171 might help brain tumor patients.
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must log in to post a comment.